• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company

    11/14/25 6:47:07 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Sotera Health Company

    (Name of Issuer)


    Common Stock, $0.01 par value per share

    (Title of Class of Securities)


    83601L102

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    Darsana Capital Partners LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.8 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    Darsana Capital Partners GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.8 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    Darsana Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    Darsana Capital GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.8 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    83601L102


    1Names of Reporting Persons

    Anand Desai
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.8 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sotera Health Company
    (b)Address of issuer's principal executive offices:

    9100 South Hills Blvd, Suite 300, Broadview Heights, OH 44147
    Item 2. 
    (a)Name of person filing:

    Darsana Capital Partners LP Darsana Capital Partners GP LLC Darsana Master Fund LP Darsana Capital GP LLC Anand Desai
    (b)Address or principal business office or, if none, residence:

    Darsana Capital Partners LP 40 WEST 57TH STREET, 22ND FLOOR, NEW YORK, NY, 10019 Darsana Capital Partners GP LLC 40 WEST 57TH STREET, 22ND FLOOR, NEW YORK, NY, 10019 Darsana Master Fund LP 40 WEST 57TH STREET, 22ND FLOOR, NEW YORK, NY, 10019 Darsana Capital GP LLC 40 WEST 57TH STREET, 22ND FLOOR, NEW YORK, NY, 10019 Anand Desai 40 WEST 57TH STREET, 22ND FLOOR, NEW YORK, NY, 10019
    (c)Citizenship:

    Darsana Capital Partners LP - Delaware Darsana Capital Partners GP LLC - Delaware Darsana Master Fund LP - Cayman Islands Darsana Capital GP LLC - Delaware Anand Desai - United States
    (d)Title of class of securities:

    Common Stock, $0.01 par value per share
    (e)CUSIP No.:

    83601L102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Darsana Capital Partners LP - 25,000,000 Darsana Capital Partners GP LLC - 25,000,000 Darsana Master Fund LP - 25,000,000 Darsana Capital GP LLC - 25,000,000 Anand Desai - 25,000,000
    (b)Percent of class:

    Darsana Capital Partners LP - 8.8% Darsana Capital Partners GP LLC - 8.8% Darsana Master Fund LP - 8.8% Darsana Capital GP LLC - 8.8% Anand Desai - 8.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Darsana Capital Partners LP - 0 Darsana Capital Partners GP LLC - 0 Darsana Master Fund LP - 0 Darsana Capital GP LLC - 0 Anand Desai - 0

     (ii) Shared power to vote or to direct the vote:

    Darsana Capital Partners LP - 25,000,000 Darsana Capital Partners GP LLC - 25,000,000 Darsana Master Fund LP - 25,000,000 Darsana Capital GP LLC - 25,000,000 Anand Desai - 25,000,000

     (iii) Sole power to dispose or to direct the disposition of:

    Darsana Capital Partners LP - 0 Darsana Capital Partners GP LLC - 0 Darsana Master Fund LP - 0 Darsana Capital GP LLC - 0 Anand Desai - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Darsana Capital Partners LP - 25,000,000 Darsana Capital Partners GP LLC - 25,000,000 Darsana Master Fund LP - 25,000,000 Darsana Capital GP LLC - 25,000,000 Anand Desai - 25,000,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    All of the securities reported in this Schedule 13G are directly owned by advisory clients of Darsana Capital Partners LP. None of those advisory clients, other than Darsana Master Fund LP, may be deemed to beneficially own more than 5% of the Common Stock, $0.01 par value.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see Exhibit B attached hereto.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Darsana Capital Partners LP
     
    Signature:By: Darsana Capital Partners GP LLC, Its General Partner, By: /s/ Anand Desai
    Name/Title:Anand Desai / Chief Executive Officer
    Date:11/14/2025
     
    Darsana Capital Partners GP LLC
     
    Signature:/s/ Anand Desai
    Name/Title:Anand Desai / Chief Executive Officer
    Date:11/14/2025
     
    Darsana Master Fund LP
     
    Signature:By: Darsana Capital GP LLC, Its General Partner, By: /s/ Anand Desai
    Name/Title:Anand Desai / Chief Executive Officer
    Date:11/14/2025
     
    Darsana Capital GP LLC
     
    Signature:/s/ Anand Desai
    Name/Title:Anand Desai / Chief Executive Officer
    Date:11/14/2025
     
    Anand Desai
     
    Signature:/s/ Anand Desai
    Name/Title:Anand Desai
    Date:11/14/2025

    Comments accompanying signature:  * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
    Exhibit Information

    Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification

    Get the next $SHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    11/13/2025$19.00Outperform
    BMO Capital Markets
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registr

    11/6/25 4:37:01 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results

    Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024Raising 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and reaffirming net revenues outlook range of 4.5% - 6.0%, on a constant currency basis CLEVELAND, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sotera Health Comp

    11/4/25 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Third-Quarter 2025 Earnings Release Date

    CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A

    10/21/25 5:13:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company

    SCHEDULE 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/25 6:47:07 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company

    SCHEDULE 13G/A - Sotera Health Co (0001822479) (Subject)

    11/12/25 4:25:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 8-K filed by Sotera Health Company

    8-K - Sotera Health Co (0001822479) (Filer)

    11/10/25 4:06:11 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gtcr Investment Xi Llc sold $187,812,000 worth of shares (12,000,000 units at $15.65) (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    11/12/25 5:06:21 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Director Warburg Pincus & Co. sold $281,718,000 worth of shares (18,000,000 units at $15.65) (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    11/12/25 4:18:05 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Director Warburg Pincus & Co. sold $281,718,000 worth of shares (18,000,000 units at $15.65) (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    11/12/25 4:11:56 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on Sotera Health with a new price target

    BMO Capital Markets initiated coverage of Sotera Health with a rating of Outperform and set a new price target of $19.00

    11/13/25 9:17:08 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health upgraded by Goldman with a new price target

    Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

    5/5/25 8:27:32 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Goldman initiated coverage on Sotera Health with a new price target

    Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

    12/6/24 8:14:45 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results

    Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024Raising 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and reaffirming net revenues outlook range of 4.5% - 6.0%, on a constant currency basis CLEVELAND, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sotera Health Comp

    11/4/25 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Third-Quarter 2025 Earnings Release Date

    CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations. A

    10/21/25 5:13:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results

    Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues outlook to 4.5% - 6.0% and Adjusted EBITDA outlook to 6.0% - 7.5%, on a constant currency basis CLEVELAND, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera He

    8/8/25 7:30:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/12/24 5:53:58 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care